Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome
View Patent ↗Myelodysplastic syndromes can be treated or ameliorated by the administration of substance P analogs as disclosed herein.
1. A method of treating myelodysplastic syndrome in a human comprising administering to a human in need thereof an effective amount of a substance P analog consisting of Z 1 -RPKPQQFFMeGIyLM(O 2 )-Z 2 , wherein Z 1 is NH 2 and Z 2 is C(O)NH 2 (SEQ ID NO: 11).
2. The method of claim 1 wherein the myelodysplastic syndrome is refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia and ringed sideroblasts, refractory anemia with excess blasts I and II, 5q syndrome or myelodysplasia unclassifiable.
3. The method of claim 2 , wherein the myelodysplastic syndrome is refractory anemia with excess blasts I and II.
4. The method of claim 1 wherein administration of the substance P analog results in an increase in leukocytes, lymphocytes, neutrophils, band cells, monocytes, granulocytes, erythrocytes, eosinophils, basophils or platelets in the human.
5. The method of claim 4 wherein the lymphocytes are T lymphocytes or B lymphocytes.
6. The method of claim 1 wherein the substance P analog is administered by injection.
7. The method of claim 6 wherein the substance P analog is administered intramuscularly.
8. The method of claim 6 wherein the substance P analog is administered subcutaneously.
9. The method of claim 6 wherein the substance P analog is administered intradermally.
10. The method of claim 1 wherein the substance P analog is administered by inhalation.
11. The method of claim 10 wherein the substance P analog is administered intranasally.
12. The method of claim 10 wherein the substance P analog is administered by nebulizer or inhaler.
13. The method of claim 1 wherein administration of the substance P analog results in increased differentiation of high proliferative potential-stem and progenitor cells (HPP-SP cells), colony forming cells-granulocyte, erythroid, macrophage, megakaryocyte cells (CFC-GEMM cells), granulocyte-macrophage-colony forming cells (GM-CFC), megakaryocyte-colony forming cells (Mk-CFC), T-lymphocyte-colony forming cells (T-CFC), B-lymphocyte-colony forming cells (B-CFC), colony forming unit—megakaryocyte cells (CFU-Mk cells), blast forming unit—erythroid cells (BFU-E cells), colony forming unit—erythroid cells (CFU-E cells), or colony forming unit—granulocyte/macrophage cells (CFU-GM cells).
14. The method of claim 13 , wherein differentiation of a cell population selected from BFU-E, CFU-E, CFU-GM and CFU-Mk cells is increased.
15. The method of claim 1 wherein administration of the substance P analog results in increased proliferation of high proliferative potential-stem and progenitor cells HPP-SP cells, CFC-GEMM cells, GM-CFC, Mk-CFC, T-CFC, B-CFC, CFU-Mk cells, BFU-E cells, colony forming unit—erythroid cells (CFU-E cells), or colony forming unit—granulocyte/macrophage cells (CFU-GM cells).